李进 - 同济大学

个人简介

主持科研项目肿瘤新药I期临床研究的标准化和智能化研究及应用示范（19431908200）；项目来源：上海市科学技术委员会；起止年月：2019.12 -2022.11.30；资助金额：100万科技部非传染性疾病防控研究（2017YFC1308902），胃癌靶向治疗新技术研究-靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究；项目来源：中华人民共和国科技部；起止年月：2017.07-2020.12；资助金额：770万复发转移大肠癌的治疗新策略（2016ZX-07-003）；项目来源：国家卫生计生委医药卫生科技发展研究中心；起止年月：2016.11-2018.12；资助金额：1000万基于外显子测序技术筛选胃癌复发转移新基因CDH4突变及其功能研究；项目来源：国家自然科学基金；起止年月：2018.01-2020.12；资助金额：55万国际标准抗肿瘤新药临床试验平台建设（2012ZX09303-018-002）；项目来源：国家十二五重大攻关计划课题；起止年月：2012.01-2017.12；资助金额：1400万获奖成果 2014年“胃癌发生发展的分子机制研究与临床治疗新策略的建立和应用《国家教育部科技进步》二等奖。（排名第1） 2016年结直肠癌个体化治疗策略创新与应用《国家科技进步奖》二等奖 (排名第3)

研究领域

恶性肿瘤（胃肠肿瘤）的内科治疗晚期肿瘤分子靶向治疗及免疫治疗新药I期临床研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Duan, X., X. Xu, Y. Zhang, Y. Gao, J. Zhou, and J. Li, DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18. Cancer Sci, 2022. Xu, X., X. Duan, S. Wang, Y. Zhang, Y. Gao, X. Xu, G. Yeerkenbieke, J. Zhou, and J. Li, Special issue "The advance of solid tumor research in China": Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signaling. Int J Cancer, 2022. Qin, S., J. Li, et al. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. BioDrugs, 2021. 35(4): p. 445-458. Li, J., et al, Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. Adv Ther, 2020. 37(11): p. 4585-4598. Li J, Qin SK, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496. Xu, JM, … , Li, J; Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study , Journal of Clinical Oncology, 2018, 36(4): 350-358. Qin, SK; Li, J; et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial , Journal of Clinical Oncology, 2018, 36(30): 3031-3039. Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018 Jan;38(1):325-376. Liu x, Zhang X, Li J, et al. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 2017 Nov 15;141(10):2093-2102. Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017 Jan 19;10(1):22.